|
|
Who's
afraid of n-6 polyunsaturated fatty acids? Methodological considerations for
assessing whether they are harmful
Berry
EM
Department
of Human Nutrition and Metabolism, Faculty of Medicine, Hebrew University
Hadassah Medical School, Jerusalem, Israel. Berry@md2.huji.ac.il
N-6
fatty acids are essential for normal growth, development and health, and so
extreme care is necessary before deciding that they are harmful.
Theoretical and epidemiological evidence suggests the involvement of n-6
polyunsaturated fatty acids (PUFAs) in disease progression or prevention;
however, n-6 function cannot be considered in isolation but needs to be seen as
part of the complex of nutrient interactions with n-3 fatty acids (which compete
for the same enzymatic pathways) and antioxidants.
Insulin sensitivity might be the common factor relating disease to fatty acid
metabolism both within and between the fatty acid pathways.
High linoleate to arachidonate concentrations have been observed in insulin
resistance, diabetic complications and some tumours, but these are
multifactorial processes that include many lifestyle determinants and it is
therefore wrong to condemn only n-6 fatty acids in their etiology.
The results based on the criteria for assessing diet and disease are still
insufficient to declare n-6 fatty acids a serious health risk; at most, the
verdict should be "not proven".
The question may never be conclusively answered not only because prospective
dietary intervention trials (unlike those with n-3 fish oil capsules) are
fraught with dosage and compliance problems, but also because of high background
linoleate consumption.
Tissue fatty acid composition may be a suitable biomarker for PUFA intake but
there are many theoretical and methodological problems concerning other suitable
markers because of the multiplicity of their biological effects.
Before making evidence-based dietary recommendations, future research should
consider:
1) how n-3 and n-6 dietary PUFAs affect the physiological balance
(dose-response) of their derivatives such as eicosanoids and the
newly-discovered fatty acid amides;
2) the metabolic interactions between n-6 and n-3 fatty acid pathways (including
gene-nutrient effects);
3) the need for antioxidant cover (quantity and quality);
4) prospective intervention trials.
PMID:
11590994 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11590994&dopt=Abstract
|